ArticleCureus2025
Efficacy of Losartan Potassium and Benazepril in Hypertensive Patients With Insulin Resistance: Impact on Blood Pressure, Insulin Sensitivity, and Diabetes Risk.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Hypertension and insulin resistance (IR) often coexist, significantly increasing the risk of type 2 diabetes and cardiovascular disease. IR plays a key role in metabolic syndrome, promoting endothelial dysfunction and impairing glucose metabolism. Angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) are commonly prescribed for hypertension, but their differential effects on insulin sensitivity and diabetes risk remain unclear. This study compares the effects of losartan potassium (LP) (ARBs) and benazepril (ACEIs) on blood pressure control, insulin sensitivity, and metabolic parameters in hypertensive patients with IR. Methods A prospective cohort study was conducted from September 2023 to September 2024 at Khyber Teaching Hospital, Peshawar and Lahore Medical and Dental College, Lahore. A total of 364 hypertensive patients with IR were included. Based on physician-prescribed treatment, patients were categorized into two groups: Group A received benazepril (10 mg/day), and Group B received LP (50 mg/day). Primary outcomes included blood pressure control, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) scores, fasting glucose, and lipid profiles, measured at baseline and regular follow-ups over 12 months. Patient adherence was monitored through self-reports and prescription refill checks. Missing data were handled using multiple imputations. Statistical analyses included independent t-tests, paired t-tests, repeated-measures ANOVA, and multivariate regression models, with a significance level set at p < 0.05. Results Both treatments significantly reduced blood pressure, but LP demonstrated greater efficacy, with superior reductions in systolic (26.4 mmHg vs. 24.7 mmHg) and diastolic (15.3 mmHg vs. 13.6 mmHg) readings (p < 0.05). HOMA-IR scores improved more in the losartan group (1.7 vs. 1.4; p = 0.02), along with a greater decrease in fasting glucose, suggesting a potential protective effect against diabetes development. Lipid profile improvements were comparable between groups. Adherence rates were similar, with a dropout rate of 8.2% and no major adverse events. Conclusions LP was more effective than benazepril in lowering blood pressure and improving insulin sensitivity, which may contribute to a lower diabetes risk in hypertensive patients with IR. A randomized controlled trial with longer follow-up is recommended to confirm these findings and assess long-term metabolic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.